Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2021-02-03
Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis
2021-02-03
Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
2021-01-08
The beginning of the end for Type I diabetes: A new view from immunotherapy science
2020-09-07
Imcyse Announces the Appointment of Denis Bedoret as Chief Executive Officer
2020-07-28
Imcyse Awarded Subsidy from the Walloon Region for Neuromyelitis Optica Spectrum Disorder Study

©imcyse 2023